IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: A single blind randomised controlled phase I study

Journal of Immune Based Therapies and Vaccines

Volumn 5, Issue , 2007, Pages

  Brignone, Chrystelle ^a   Grygar, Caroline ^a   Marcu, Manon ^a   Perrin, Gaëlle ^a   Triebel, Frédéric ^a  

^a Immutep SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; IMMUNOSTIMULATING AGENT; IMP 321; INTERLEUKIN 2; RECOMBINANT HEPATITIS B VACCINE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; APHTHOUS STOMATITIS; ARTICLE; ASTHENIA; BACKACHE; CELL DENSITY; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HERPES SIMPLEX; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOPOTENTIATION; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LYMPHOCYTE ACTIVATION; MALE; MONOTHERAPY; MYALGIA; NAUSEA; NORMAL HUMAN; PAPULAR RASH; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SINGLE BLIND PROCEDURE; SINUSITIS; T LYMPHOCYTE; TH1 CELL; URINARY TRACT INFECTION; VACCINATION;

EID: 34247266009     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-5-5     Document Type: Article

References (16)

1. Prasad KS Andre P He M Bao M Manganello J Phillips DR Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling Proc Natl Acad Sci U S A 2003 100 12367-12371 10.1073/pnas.2032886100 14519852 218764
2. El mir S Triebel F A soluble LAG-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens J Immunol 2000 164 5583-5589 10820232
3. Andreae S Piras F Burdin N Triebel F Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223) J Immunol 2002 168 3874-3880 11937541
4. Buisson S Triebel F MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine receptor expression by human dendritic cells. Vaccine 2003 21 862-868 10.1016/S0264-410X(02)00533-9 12547595
5. Prigent P Mir SE Dreano M Triebel F LAG-3 induces tumor regression and antitumor immune responses in vivo Eur J Immunol 1999 29 3867-3876 10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E 10601994
6. Cappello P Triebel F Iezzi M Caorsi C Quaglino E Lollini PL Amici A Di Carlo E Musiani P Giovarelli M Forni G LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/ c mice Cancer Res 2003 63 2518-2525 12750275
7. Di Carlo E Cappello P Sorrentino C D'Antuono T Pellicciotta A Giovarelli M Forni G Musiani P Triebel F Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway J Pathol 2005 205 82-91 10.1002/path.1679 15586367
8. Andreae S Buisson S Triebel F MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223) Blood 2003 102 2130-2137 10.1182/blood-2003-01-0273 12775570
9. Rothenfusser S Hornung V Ayyoub M Britsch S Towarowski A Krug A Sarris A Lubenow N Speiser D Endres S Hartmann G CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro Blood 2004 103 2162-2169 10.1182/ blood-2003-04-1091 14630815
10. Casati C Camisaschi C Rini F Arienti F Rivoltini L Triebel F Parmiani G Castelli C Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity Cancer Res 2006 66 4450-4460 10.1158/0008-5472.CAN-05-2728 16618772
11. Huard B Prigent P Pages F Bruniquel D Triebel F T cell MHC class II molecules downregulate CD4+ T cell clone response following LAG-3 binding Eur J Immunol 1996 26 1180-1186 10.1002/eji.1830260533 8647185
12. Bocher WO Herzog-Hauff S Schlaak J Meyer zum Buschenfeld KH Lohr HF Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: Stimulation of the in vitro antibody response by interferon gamma Hepatology 1999 29 238-244 10.1002/hep.510290120 9862872
13. Halperin SA Van Nest G Smith B Abtahi S Whiley H Eiden JJ A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant Vaccine 2003 21 2461-2467 10.1016/S0264-410X(03)00045-8 12744879
14. Cooper CL Davis HL Morris ML Efler SM Adhami MA Krieg AM Cameron DW Heathcote J CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study J Clin Immunol 2004 24 693-701 10.1007/s10875-004-6244-3 15622454
15. Cooper CL Davis HL Morris ML Efler SM Krieg AM Li Y Laframboise C Al Adhami MJ Khaliq Y Seguin I Cameron DW Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine Vaccine 2004 22 3136-3143 10.1016/j.vaccine.2004.01.058 15297066
16. Speiser DE Lienard D Rufer N Rubio-Godoy V Rimoldi D Lejeune F Krieg AM Cerottini JC Romero P Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 J Clin Invest 2005 115 739-746 10.1172/JCI200523373 15696196 546459